Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-8400 in Moderate to Severe Plaque Psoriasis
NCT01899729Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- May 2013
- Primary completion
- Apr 2014
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of bazlitoran in plaque psoriasis, sponsored by Aceragen, Inc.. Started May 2013; status: completed.
02
Drugs
bazlitoran
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01899729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899729.